What's Happening?
The Centers for Medicare & Medicaid Services (CMS) has finalized a higher hospital outpatient payment level for the Gastric Alimetry test, increasing Medicare payment by approximately 144% in 2027. This decision, announced by Alimetry, a medical technology
company, is expected to broaden hospital access to the wearable gastric mapping test for patients suffering from chronic nausea, vomiting, fullness, and abdominal pain. In its 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule, CMS reassigned CPT code 0868T from Ambulatory Payment Classification (APC) 5723 (Level 3) to APC 5724 (Level 4 Diagnostic Tests and Related Services). This change results in a national unadjusted payment of $1,048.77, which is about 2.4 times the previous Level 3 rate, effective January 1, 2027. CMS cited recommendations from its Advisory Panel on Hospital Outpatient Payment, hospital cost data, and public comments in support of this reclassification. Separately, Alimetry is launching updated Gastric Alimetry reports on November 19, which will include automated phenotype classification and new reference ranges for adolescents, following FDA 510(k) clearance in September 2026.
Why It's Important?
This significant increase in Medicare reimbursement for the Gastric Alimetry test is crucial for improving access to advanced diagnostic tools for millions of Americans suffering from chronic gastrointestinal disorders. Many patients with conditions like gastroparesis and functional dyspepsia endure years of symptoms without a clear diagnosis. The higher payment rate removes a substantial financial barrier for hospitals, making it more feasible for them to offer this specialized test. This can lead to earlier and more accurate diagnoses, allowing clinicians to tailor treatment plans more effectively. For patients, a clearer understanding of whether their symptoms are linked to stomach motility or sensory issues can significantly improve their quality of life and guide subsequent medical decisions. The introduction of automated phenotype reports and adolescent reference ranges further enhances the test's utility, providing more precise and age-appropriate diagnostic information.
What's Next?
Effective January 1, 2027, hospitals across the U.S. are expected to have greater financial incentive to adopt and offer the Gastric Alimetry test. This could lead to a wider availability of the diagnostic system, particularly in areas where access to specialized GI care might be limited. Alimetry will also be rolling out updated reports with automated phenotype classification and adolescent reference ranges starting November 19, which will immediately enhance the diagnostic utility for clinicians. While the reassignment is a payment classification decision, not a Medicare coverage determination, applicable coverage policies and payer requirements will continue to apply, and actual payments will vary by geography and hospital. Alimetry will likely focus on educating healthcare providers and hospital administrators about the new payment structure and the enhanced features of its system to drive adoption and utilization.
Beyond the Headlines
The CMS decision reflects a broader recognition of the value of innovative diagnostic technologies in managing complex chronic conditions. It highlights the ongoing effort to align reimbursement rates with the actual costs and clinical benefits of advanced medical devices. This move could encourage further investment in gastrointestinal diagnostics, fostering innovation in a field where diagnostic clarity has historically been challenging. From a patient perspective, this represents a step towards more personalized medicine, where diagnoses are based on objective physiological data rather than subjective symptom reporting alone. The integration of AI-assisted analysis and automated phenotyping in medical diagnostics also points to the future of healthcare, where technology plays an increasingly central role in improving diagnostic accuracy and efficiency. This could set a precedent for other novel diagnostic tools seeking appropriate reimbursement to ensure wider patient access.













